ArticleJournal of molecular histology2025
Nuclear receptor FXR inhibits ferroptosis to alleviate hepatic ischemia-reperfusion injury by targeting GPX4 in a mouse model.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preconditioning with sufentanil confers protective effects in transplantation by attenuating hepatic ischemia-reperfusion injury.World journal of transplantation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Ischemia-reperfusion injury is a common complication in hepatic surgery, which seriously affects the surgical prognosis. Ferroptosis is a novel programmed cell death mode involved in hepatic ischemia-reperfusion injury (HIRI). Recent studies have shown that nuclear receptor FXR can alleviate HIRI, but the mechanism is not fully understood. In this study, we explored the potential regulatory mechanism of FXR in HIRI by using wild-type mice, FXR knockout mice, and AML12 cells. Results show that FXR was negatively correlated with HIRI-induced ferroptosis, and deletion of FXR promotes ferroptosis induced by HIRI. Activation of FXR was able to promote GPX4 expression and inhibit ferroptosis. However, the co-treatment of GPX4 inhibitor and FXR ligand weakened the inhibitory effect of FXR on promoting GPX4 expression and ferroptosis. Luciferase and EMSA results suggest that FXR regulates GPX4 transcriptional expression by binding to DR5 upstream of the GPX4 initiation codon. Our results suggest that FXR can inhibit HIRI-induced ferroptosis by targeting the transcriptional expression of GPX4. It contributes to a better understanding of the role of FXR in HIRI. In addition, our findings provide potential therapeutic options for the intervention of ischemia-reperfusion injury in surgery.
Indexed as
Identifiers
40742574What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.